Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.

Friedlaender A, Drilon A, Weiss GJ, Banna GL, Addeo A.

Cancer Treat Rev. 2020 Feb 7;85:101978. doi: 10.1016/j.ctrv.2020.101978. [Epub ahead of print] Review.

PMID:
32062493
2.

Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients.

Bersanelli M, Scala S, Affanni P, Veronesi L, Colucci ME, Banna GL, Cortellini A, Liotta F.

Immunotherapy. 2020 Feb 12. doi: 10.2217/imt-2019-0200. [Epub ahead of print] No abstract available.

PMID:
32046555
3.

Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer.

Banna GL, Urzia V, Benanti C, Pitrè A, Lipari H, Di Quattro R, De Giorgi U, Schepisi G, Basso U, Bimbatti D, Rundo F, Libra M, Malatino L.

Support Care Cancer. 2020 Jan 20. doi: 10.1007/s00520-020-05311-5. [Epub ahead of print]

PMID:
31960124
4.

Corrigendum to "Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica" [Crit. Rev. Oncol. Hematol. 137 (2019) (May) 154-164].

Banna GL, Nicolai N, Palmieri G, Ottaviano M, Balzarini L, Barone D, Basso U, Bavila A, Bertoni F, Calliada F, Cai T, Carrafiello G, Condello C, Da Pozzo L, Di Nardo D, Fornarini G, Galetti TP, Garolla A, Giannatempo P, Guerra L, La Spina S, Malatino L, Marchiano' A, Monti M, Morbiato FF, Morelli F, Nole' F, Palazzi S, Procopio G, Rosti G, Sacco C, Salvetti A, Salvioni R, Sava T, Secondino S, Serpentini S, Spreafico C, Tavolini IM, Valcamonico F, Verri E, Zucali P, De Giorgi U.

Crit Rev Oncol Hematol. 2020 Jan 9;146:102865. doi: 10.1016/j.critrevonc.2020.102865. [Epub ahead of print] No abstract available.

PMID:
31927391
5.

[Vinflunine: still an option for patients with advanced urothelial carcinoma following immune-checkpoint inhibitors?]

Banna GL, Rundo F, Lipari H, Di Quattro R, Urzia V, Libra M, Malatino L.

Recenti Prog Med. 2019 Dec;110(12):615-618. doi: 10.1701/3278.32520. Italian.

PMID:
31909764
6.

Identifying successful biomarkers for patients with non-small-cell lung cancer.

Friedlaender A, Bauml J, Banna GL, Addeo A.

Lung Cancer Manag. 2019 Nov 14;8(3):LMT17. doi: 10.2217/lmt-2019-0009. No abstract available.

7.

Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era.

Friedlaender A, Banna GL, Buffoni L, Addeo A.

Curr Oncol Rep. 2019 Nov 25;21(12):107. doi: 10.1007/s11912-019-0852-9. Review.

PMID:
31768759
8.

Tumor Mutation Burden-From Doubts to Concerns-In Reply.

Addeo A, Banna GL, Weiss GJ.

JAMA Oncol. 2019 Oct 24. doi: 10.1001/jamaoncol.2019.4141. [Epub ahead of print] No abstract available.

PMID:
31647493
9.

Prophylactic cranial irradiation in extensive disease small cell lung cancer: An endless debate.

Picardi C, Caparroti F, Di Maio M, Kaššák F, Banna GL, Addeo A.

Crit Rev Oncol Hematol. 2019 Nov;143:95-101. doi: 10.1016/j.critrevonc.2019.08.010. Epub 2019 Sep 12. Review.

PMID:
31563079
10.

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.

Pujol JL, Coffy A, Camerini A, Kotsakis A, Mencoboni M, Gusella M, Pasini F, Pezzuto A, Banna GL, Bilir C, Samantas E, Barlesi F, Roch B, Guillou A, Daurès JP.

PLoS One. 2019 Aug 20;14(8):e0220988. doi: 10.1371/journal.pone.0220988. eCollection 2019.

11.

The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy.

Banna GL, Olivier T, Rundo F, Malapelle U, Fraggetta F, Libra M, Addeo A.

Front Med (Lausanne). 2019 Jul 31;6:172. doi: 10.3389/fmed.2019.00172. eCollection 2019.

12.

Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support.

De Padova S, Casadei C, Berardi A, Bertelli T, Filograna A, Cursano MC, Menna C, Burgio SL, Altavilla A, Schepisi G, Prati S, Montalti S, Chovanec M, Banna GL, Grassi L, Mego M, De Giorgi U.

Front Endocrinol (Lausanne). 2019 May 28;10:318. doi: 10.3389/fendo.2019.00318. eCollection 2019. Review.

13.

Tumor Mutation Burden-From Hopes to Doubts.

Addeo A, Banna GL, Weiss GJ.

JAMA Oncol. 2019 Jul 1;5(7):934-935. doi: 10.1001/jamaoncol.2019.0626. No abstract available.

PMID:
31145420
14.

State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough.

Bersanelli M, Buti S, De Giorgi U, Di Maio M, Giannarelli D, Pignata S, Banna GL.

Crit Rev Oncol Hematol. 2019 Jul;139:87-90. doi: 10.1016/j.critrevonc.2019.05.003. Epub 2019 May 8. Review.

PMID:
31112887
15.
16.

Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica.

Banna GL, Nicolai N, Palmieri G, Ottaviano M, Balzarini L, Barone D, Basso U, Bavila A, Bertoni F, Calliada F, Cai T, Carrafiello G, Condello C, Da Pozzo L, Di Nardo D, Fornarini G, Prayer Galetti T, Garolla A, Giannatempo P, Guerra L, La Spina S, Malatino L, Marchiano' A, Monti M, Morbiato FF, Morelli F, Nole' F, Palazzi S, Procopio G, Rosti G, Sacco C, Salvetti A, Salvioni R, Sava T, Secondino S, Serpentini S, Spreafico C, Tavolini IM, Valcamonico F, Verri E, Zucali P, De Giorgi U.

Crit Rev Oncol Hematol. 2019 May;137:154-164. doi: 10.1016/j.critrevonc.2019.03.006. Epub 2019 Mar 20. Review. Erratum in: Crit Rev Oncol Hematol. 2020 Jan 9;146:102865.

PMID:
31014511
17.

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U, Masini C, Bamias A, Garcia Del Muro X, Duran I, Powles T, Gamulin M, Zengerling F, Geczi L, Gedye C, de Ducla S, Fear S, Merseburger AS.

Eur Urol. 2019 Jul;76(1):73-81. doi: 10.1016/j.eururo.2019.03.015. Epub 2019 Mar 23.

18.

Learning from the past to design better trials in second-line treatment for mesothelioma patients.

Addeo A, Banna GL, Dietrich PY.

Ecancermedicalscience. 2018 Nov 12;12:881. doi: 10.3332/ecancer.2018.881. eCollection 2018.

19.

Gut Microbiota and Cancer: From Pathogenesis to Therapy.

Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, Torino F, Banna GL, Tonini G, Libra M.

Cancers (Basel). 2019 Jan 3;11(1). pii: E38. doi: 10.3390/cancers11010038. Review.

20.

[Influenza vaccination in advanced cancer patients undergoing immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: what data do we have for the clinical recommendation?]

Bersanelli M, Buti S, De Giorgi U, Di Maio M, Giannarelli D, Banna GL.

Recenti Prog Med. 2018 Nov;109(11):540-546. doi: 10.1701/3031.30291. Review. Italian.

PMID:
30565573
21.

Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis.

Camerini A, Banna GL, Cinieri S, Pezzuto A, Mencoboni M, Rosetti F, Figueiredo A, Rizzo P, Ricci A, Langenhoven L, Santo A, Addeo A, Amoroso D, Barata F.

Clin Transl Oncol. 2019 Jun;21(6):790-795. doi: 10.1007/s12094-018-1989-y. Epub 2018 Nov 17.

PMID:
30448956
22.

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Addeo A, Banna GL.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S287-S289. doi: 10.21037/tlcr.2018.07.09. No abstract available.

23.

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Addeo A, Banna GL.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S283-S286. doi: 10.21037/tlcr.2018.07.10. No abstract available.

24.

The crucial role of predicting brain metastases development in non-small cell lung cancer patients.

Addeo A, Banna GL.

J Thorac Dis. 2018 Sep;10(Suppl 26):S3305-S3307. doi: 10.21037/jtd.2018.08.95. No abstract available.

25.

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, De Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, La Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, De Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, De Tursi M, Di Maio M, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S.

Immunotherapy. 2018 Oct;10(14):1229-1239. doi: 10.2217/imt-2018-0080.

PMID:
30326787
26.

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection.

Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A, Cortinovis DL.

Crit Rev Oncol Hematol. 2018 Sep;129:27-39. doi: 10.1016/j.critrevonc.2018.06.016. Epub 2018 Jun 23. Review.

PMID:
30097235
27.

Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.

Banna GL, Camerini A, Bronte G, Anile G, Addeo A, Rundo F, Zanghì G, Lal R, Libra M.

Anticancer Res. 2018 Jun;38(6):3689-3697. doi: 10.21873/anticanres.12647.

PMID:
29848729
28.

Treatment and prognostic factors of patients with thymic epithelial tumors at first recurrence or progression.

Banna GL, Sheel A, Sheel V, Bille A, Routledge T, Fernando S, Nair A, Lal R.

Future Oncol. 2017 Nov;13(27):2429-2439. doi: 10.2217/fon-2017-0236. Epub 2017 Nov 10.

29.

Consider Quality of Life to Improve Quality of Cancer Guidelines.

Schepisi G, Banna GL, De Giorgi U.

JAMA Intern Med. 2017 Oct 1;177(10):1537. doi: 10.1001/jamainternmed.2017.3694. No abstract available.

PMID:
28973270
30.

Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer.

Banna GL, Torino F, Marletta F, Santagati M, Salemi R, Cannarozzo E, Falzone L, Ferraù F, Libra M.

Front Pharmacol. 2017 Sep 1;8:603. doi: 10.3389/fphar.2017.00603. eCollection 2017. Review.

31.

Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.

Banna GL, Parra HJS, Castaing M, Dieci MV, Anile G, Nicolosi M, Strano S, Marletta F, Guarneri V, Conte P, Lal R.

Anticancer Res. 2017 Jul;37(7):3723-3728.

PMID:
28668866
32.

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.

Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S.

Clin Lung Cancer. 2018 Jan;19(1):93-104. doi: 10.1016/j.cllc.2017.05.016. Epub 2017 Jun 1.

PMID:
28645631
33.

Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.

Banna GL, Anile G, Russo G, Vigneri P, Castaing M, Nicolosi M, Strano S, Gieri S, Spina R, Patanè D, Calcara G, Fraggetta F, Marletta F, Stefano A, Ippolito M.

Oncology. 2017;92(1):39-47. doi: 10.1159/000448005. Epub 2016 Nov 11.

PMID:
27832654
34.

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.

Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, Novello S.

Lung Cancer. 2016 May;95:73-81. doi: 10.1016/j.lungcan.2016.02.011. Epub 2016 Feb 26.

35.

How to develop novel treatments for EGFR-mutant lung cancer.

Banna GL, Tiseo M.

Future Oncol. 2015;11(17):2375-8. doi: 10.2217/FON.15.172. Epub 2015 Aug 13. No abstract available.

PMID:
26270133
36.

Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology.

Aurilio G, Gori S, Nolè F, Pruneri G, Coati F, Torri V, Lunardi G, Atzori F, La Verde N, Banna GL, Rossi A, Del Mastro L, Di Fabio F, Marcon I, Gebbia V, Loupakis F, Orlando L, Ciuffreda L, Amadio P, Luppi G, Redana S, Filippelli G, Gentile A, Collovà E.

Tumori. 2016 Jan-Feb;102(1):108-13. doi: 10.5301/tj.5000383. Epub 2015 Jul 2.

PMID:
26166216
37.

Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma.

Scandurra G, Scibilia G, Banna GL, D'Agate G, Lipari H, Gieri S, Scollo P.

J Gynecol Oncol. 2015 Apr;26(2):118-24. doi: 10.3802/jgo.2015.26.2.118. Epub 2015 Feb 4.

38.

A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer.

Banna GL, Lipari H, Nicolosi M, Basile A, Fraggetta F, Vaglica M, Marletta F, Urso OE, Ippolito M, Terminella A, Saita S.

Med Oncol. 2013 Jun;30(2):533. doi: 10.1007/s12032-013-0533-8. Epub 2013 Mar 20.

PMID:
23512427
39.

Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.

Gebbia V, Bellavia M, Banna GL, Russo P, Ferraù F, Tralongo P, Borsellino N.

Clin Lung Cancer. 2013 Jul;14(4):390-8. doi: 10.1016/j.cllc.2012.11.007. Epub 2013 Jan 10.

PMID:
23313173
40.

Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors.

Di Maio M, Bria E, Banna GL, Puglisi F, Garassino MC, Lorusso D, Perrone F.

Anticancer Drugs. 2013 Feb;24(2):99-111. doi: 10.1097/CAD.0b013e328359d7ba. Review.

PMID:
23165435
41.

Intensified chemotherapy with stem-cell rescue in germ-cell tumors.

Simonelli M, Rosti G, Banna GL, Pedrazzoli P; Italian Germ cell cancer Group (IGG); Gruppo Italiano Trapianto Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO).

Ann Oncol. 2012 Apr;23(4):815-22. doi: 10.1093/annonc/mdr403. Epub 2011 Sep 23. Review.

42.

CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases.

Paratore S, Banna GL, D'Arrigo M, Saita S, Iemmolo R, Lucenti L, Bellia D, Lipari H, Buscarino C, Cunsolo R, Cavallaro S.

Cancer Biomark. 2011-2012;10(2):79-89. doi: 10.3233/CBM-2011-0232.

PMID:
22430135
43.

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).

Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E; ISA Co-Authors, Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, Zanon E.

Lung Cancer. 2011 Jul;73(1):78-88. doi: 10.1016/j.lungcan.2010.10.020. Epub 2010 Dec 8.

PMID:
21144614
44.

Anticancer oral therapy: emerging related issues.

Banna GL, Collovà E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferraù F.

Cancer Treat Rev. 2010 Dec;36(8):595-605. doi: 10.1016/j.ctrv.2010.04.005. Epub 2010 Jun 8. Review.

PMID:
20570443
45.

Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy.

Simonelli M, Banna GL, Santoro A.

Tumori. 2009 Mar-Apr;95(2):243-7.

PMID:
19579874
46.

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.

Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, De Maria R.

Clin Cancer Res. 2008 Dec 15;14(24):8205-12. doi: 10.1158/1078-0432.CCR-08-0644.

47.
48.

Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?

Banna GL, De Giorgi U, Ferrari B, Castagna L, Alloisio M, Marangolo M, Rosti G, Santoro A.

Biol Blood Marrow Transplant. 2006 Oct;12(10):1085-91.

49.

Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.

Banna GL, Bettio D, Scorsetti M, Navarria P, Simonelli M, Rodriguez Baena R, Aimar E, Gaetani P, Colombo P, Rognone F, Santoro A.

J Neurooncol. 2007 Feb;81(3):323-5. Epub 2006 Sep 23.

PMID:
17031557
50.

Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer.

Banna GL, Aversa SM, Crivellari G, Ghiotto C, Chiarion-Sileni V, Monfardini S.

Br J Cancer. 2006 May 22;94(10):1550-2. No abstract available.

Supplemental Content

Loading ...
Support Center